Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
16 results
  • Colorectal Cancer, Melanoma, Lung Cancer, Pancreatic Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations (View details on

  • Esophageal Cancer, Liver Cancer, Endometrial Cancer, Bladder Cancer, Gastric (Stomach) Cancer, Pancreatic Cancer, Sarcoma

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on

  • Pancreatic Cancer

17-429          Phase II

A Phase 1b/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer) (View details on

  • Lung Cancer, Pancreatic Cancer, Colorectal Cancer

20-671          Phase II

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation (View details on

  • Pancreatic Cancer, Ovarian Cancer, Endometrial Cancer, Chordoma, Cervical Cancer, Breast Cancer, Bladder Cancer, Esophageal Cancer, Melanoma, Lung Cancer

20-650          Phase II

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (View details on

  • Pancreatic Cancer, Lymphoma, Melanoma, Colorectal Cancer, Neuroendocrine, Head and Neck Cancer, Kidney Cancer

21-447          Phase I

An Open-Label Study of ALPN-202 Combined with PD-1 Inhibition in Subjects with Advanced Malignancies (NEON-2) (View details on

Showing 1 - 10 of 16 results